Is ABUS or GLUE more profitable?

ABUS runs the higher net margin — ABUS at 84.23% versus GLUE at -560.85%.

How have ABUS and GLUE total returns compared?

Over the past 5 years, ABUS delivered 2.19% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.

Arbutus Biopharma Corp (ABUS) vs Monte Rosa Therapeutics, Inc. (GLUE)

A side-by-side comparison of Arbutus Biopharma Corp and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$877M

$4.44HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

GLUE

Monte Rosa Therapeutics, Inc.

$836M

$9.90HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — ABUS vs GLUE

growth of $100 · dividends reinvested · last 5y

ABUS +48.3% (+8.2%/yr)GLUE -51.5% (-13.5%/yr)ABUS compounded faster over this window

ABUS GLUE

ABUS vs GLUE: by the numbers

•ABUS is the larger company ($877M vs $836M market cap).
•ABUS is profitable (84.23% net margin) while GLUE runs a net loss (-560.85%).

Metrics side by side

Valuation

Metric	ABUS	GLUE
P/E ratio	5.69	N/A
Forward P/E	6.00	N/A
P/S ratio	4.83	29.11
P/B ratio	3.39	1.72
EV / EBITDA	5.85	N/A

Profitability

Metric	ABUS	GLUE
Gross margin	99.98%	92.94%
Operating margin	-192.08%	-43.83%
Net margin	84.23%	-560.85%
ROE	59.16%	-33.06%
ROIC	54.39%	-28.69%

Growth (annualized)

Metric	ABUS	GLUE
Revenue CAGR (5Y)	85.17%	N/A
Total return CAGR (5Y)	2.19%	-12.32%

Frequently asked

Is ABUS or GLUE more profitable?: ABUS runs the higher net margin — ABUS at 84.23% versus GLUE at -560.85%.
How have ABUS and GLUE total returns compared?: Over the past 5 years, ABUS delivered 2.19% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysis Full GLUE analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio Arbutus Biopharma ROE Monte Rosa Therapeutics ROE Arbutus Biopharma operating margin Monte Rosa Therapeutics operating margin Arbutus Biopharma revenue growth Monte Rosa Therapeutics revenue growth Arbutus Biopharma free cash flow Monte Rosa Therapeutics free cash flow

Arbutus Biopharma & Monte Rosa Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.